Key Developments: Simulations Plus Inc (SLP.PH)
3.10USD
26 Oct 2011
$-0.03 (-0.63%)
$3.10
--
$4.79
$4.62
2,978
8,328
$4.89
$2.91
Latest Key Developments (Source: Significant Developments)
Simulations Plus Inc Announces Quarterly Cash Dividend
Simulations Plus Inc announced that The Board of Directors have declared its next ongoing quarterly cash dividend of $0.03 per share, an increase of $0.01 per share over the $0.02 per share that was planned after the accelerated dividend distribution of $0.03 per share for the expected May, August, and November 2013 distributions. This dividend will be distributed on, May 10, 2013, for shareholders of record as of May 7, 2013. Full Article
Simulations Plus Inc Announces Accelerated Quarterly Cash Dividend
Simulations Plus Inc announced that the Board of Director has declared its next ongoing quarterly cash dividend of $0.05 per share. In addition, the Board of Directors decided to pay a $0.03 per share portion of the intended $0.05 per share dividend for the following three quarters to its shareholders. This accelerated payment will be distributed on December 28, 2012, for shareholders of record as of December 24, 2012. Full Article
Simulations Plus Inc Quarterly Cash Dividend
Simulations Plus Inc announced that its board of directors has declared its next ongoing quarterly cash dividend of $0.05 per share to its shareholders will be distributed on November 13, 2012, for shareholders of record as of November 8, 2012. Full Article
Simulations Plus, Inc. Announces Quarterly Cash Dividend
Simulations Plus, Inc. announced that its board of directors has declared its next ongoing quarterly cash dividend of $0.05 per share to its shareholders will be distributed on Friday, August 10, 2012, for shareholders of record as of Tuesday, August 7, 2012. Full Article
Simulations Plus, Inc. Announces Next Quarterly Cash Dividend
Simulations Plus, Inc. announced that its board of directors has declared its next ongoing quarterly cash dividend of $0.05 per share to its shareholders will be distributed on May 8, 2012, for shareholders of record as of April 27, 2012. Full Article
Simulations Plus, Inc. Announces Further Success In Malaria Drug Design Project
Simulations Plus, Inc. announced that further testing shows that the newest molecule the Company has designed to inhibit the malaria parasite is nearly three times more potent as an inhibitor of the drug-sensitive 3D7 strain of the malaria parasite than its best previous molecule. In addition, this newest molecule shows nanomolar activity against three drug-resistant strains of the malaria parasite. The term nanomolar activity refers to a concentration expressed in billionths of a mole per liter of fluid needed to inhibit 50% (“IC50”) of the parasites in a laboratory experiment. Typical drug IC50s run from millimolar (1/1000 of a mole per liter of fluid) for less potent drugs to less than 1 nanomolar for extremely potent drugs. The smaller the IC50, the smaller the amount of drug needed to have a therapeutic effect. Full Article
Simulations Plus, Inc. Announces Preliminary Success in Malaria Drug Design Project
Simulations Plus, Inc. announced that preliminary testing shows that one of the molecules it has designed to inhibit the malaria parasite has been shown to be a potent inhibitor of the malaria parasite. Dr. Robert Clark, director of life sciences for Simulations Plus, said: “We’re excited to announce that, as a result of initial testing of five of the compounds we designed to inhibit the Plasmodium falciparum malaria parasite, four of the five showed some inhibition of the parasite, and one of those four showed very potent inhibition at a level suitable to be a therapeutic agent. Of course, inhibiting the parasite does not necessarily mean that this molecule would be a good drug. There are many more properties that must be acceptable and years of development needed before that could happen. But this is a remarkable achievement nonetheless, because it demonstrates that using only predictions and design methods from our MedChem Studio, MedChem Designer, ADMET Predictor, and GastroPlus software and some public domain data, we were able to design completely new chemical structures that can hit a target. There remain a few more molecules in synthesis, and those will be tested once synthesis and purification have been completed by our synthesis company, Kalexsyn, Inc., of Kalamazoo, MI. Among those molecules are the ones we believed would be the most potent inhibitors of the malaria parasite. Full Article
Simulations Plus, Inc. Buys out Royalty Agreement
Simulations Plus, Inc. announced that it has agreed to buy out the software royalty agreement with Enslein Research of Rochester, New York, for $75,000. Full Article
Simulations Plus, Inc. Comments On FY 2012 Profit Guidance
Simulations Plus, Inc. announced that in fiscal 2012, it expects to continue trend of growth and profitability with a new record for any quarter in second quarter, layering on top of announced record first quarter revenue. Full Article
Simulations Plus, Inc. Signs Stock Purchase Agreement For Sale Of Words+ Subsidiary
Simulations Plus, Inc. announced that it has signed a Stock Purchase Agreement with the Prentke Romich Company of Wooster, Ohio (PRC) to sell Simulations Plus’ wholly owned Words+ subsidiary to PRC for $2.1 million subject to ordinary adjustments for changes in net working capital. Closing is planned for November 30, 2011. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
